Drug Trial Radar · NCT07267299
Switching From Restasis to TRYPTYR
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Apr 1, 2026
Study completion May 15, 2026
Sponsor
- Lead sponsor
- Southern College of OptometryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.
Conditions
- Dry Eye
- Eye Diseases
- Chronic Dry Eye
Interventions
acoltremon 0.003%Drug
Participants who are using restasis will be switched to acoltremon 0.003%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change between pre- and post-drop in unanesthetized Schirmer test score on Day 1Time frame: 1 day
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.